Incyte’s Monjuvi Scores In Follicular Lymphoma
Phase III success will help expand the CD19-targeting drug’s niche in lymphoma, as Incyte looks for growth beyond the coming expiry of its blockbuster Jakafi.
Phase III success will help expand the CD19-targeting drug’s niche in lymphoma, as Incyte looks for growth beyond the coming expiry of its blockbuster Jakafi.